» Articles » PMID: 33801677

Characterization of Potency of the P2Y13 Receptor Agonists: A Meta-Analysis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Apr 3
PMID 33801677
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

P2Y13 is an ADP-stimulated G-protein coupled receptor implicated in many physiological processes, including neurotransmission, metabolism, pain, and bone homeostasis. Quantitative understanding of P2Y13 activation dynamics is important for translational studies. We systematically identified PubMed annotated studies that characterized concentration-dependence of P2Y13 responses to natural and synthetic agonists. Since the comparison of the efficacy (maximum response) is difficult for studies performed in different systems, we normalized the data and conducted a meta-analysis of EC (concentration at half-maximum response) and Hill coefficient (slope) of P2Y13-mediated responses to different agonists. For signaling events induced by heterologously expressed P2Y13, EC of ADP-like agonists was 17.2 nM (95% CI: 7.7-38.5), with Hills coefficient of 4.4 (95% CI: 3.3-5.4), while ATP-like agonists had EC of 0.45 μM (95% CI: 0.06-3.15). For functional responses of endogenously expressed P2Y13, EC of ADP-like agonists was 1.76 μM (95% CI: 0.3-10.06). The EC of ADP-like agonists was lower for the brain P2Y13 than the blood P2Y13. ADP-like agonists were also more potent for human P2Y13 compared to rodent P2Y13. Thus, P2Y13 appears to be the most ADP-sensitive receptor characterized to date. The detailed understanding of tissue- and species-related differences in the P2Y13 response to ADP will improve the selectivity and specificity of future pharmacological compounds.

Citing Articles

Pharmacological Profile of the Purinergic P2Y Receptors That Modulate, in Response to ADPβS, the Vasodepressor Sensory CGRPergic Outflow in Pithed Rats.

Miguel-Martinez A, Linares-Bedolla J, Villanueva-Castillo B, Haanes K, MaassenVanDenBrink A, Villalon C Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986572 PMC: 10056196. DOI: 10.3390/ph16030475.


Purinergic P2 Receptors: Structure and Function 2.0.

Zemkova H Int J Mol Sci. 2023; 24(6).

PMID: 36982535 PMC: 10049242. DOI: 10.3390/ijms24065462.


Migraine signaling pathways: purine metabolites that regulate migraine and predispose migraineurs to headache.

Biringer R Mol Cell Biochem. 2023; 478(12):2813-2848.

PMID: 36947357 DOI: 10.1007/s11010-023-04701-7.


Extracellular ATP and its derivatives provide spatiotemporal guidance for bone adaptation to wide spectrum of physical forces.

Dsouza C, Moussa M, Mikolajewicz N, Komarova S Bone Rep. 2022; 17:101608.

PMID: 35992507 PMC: 9385560. DOI: 10.1016/j.bonr.2022.101608.


Exploring the Therapeutic Potential of Targeting Purinergic and Orexinergic Receptors in Alcoholic Neuropathy.

Madaan P, Behl T, Sehgal A, Singh S, Sharma N, Yadav S Neurotox Res. 2022; 40(2):646-669.

PMID: 35080764 DOI: 10.1007/s12640-022-00477-8.

References
1.
Foster C, Prosser D, Agans J, Zhai Y, Smith M, Lachowicz J . Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001; 107(12):1591-8. PMC: 200194. DOI: 10.1172/JCI12242. View

2.
Jacobson K, Delicado E, Gachet C, Kennedy C, von Kugelgen I, Li B . Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol. 2020; 177(11):2413-2433. PMC: 7205808. DOI: 10.1111/bph.15005. View

3.
Storey R, Husted S, Harrington R, Heptinstall S, Wilcox R, Peters G . Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007; 50(19):1852-6. DOI: 10.1016/j.jacc.2007.07.058. View

4.
Espada S, Ortega F, Molina-Jijon E, Rojo A, Perez-Sen R, Pedraza-Chaverri J . The purinergic P2Y(13) receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Free Radic Biol Med. 2010; 49(3):416-26. DOI: 10.1016/j.freeradbiomed.2010.04.031. View

5.
van Giezen J, Humphries R . Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005; 31(2):195-204. DOI: 10.1055/s-2005-869525. View